Innate Pharma receives a milestone payment for IPH2201, a monoclonal antibody licensed to Novo Nordisk A/S

IPH2201 is the third monoclonal antibody developed in collaboration with Novo Nordisk A/S expected to enter clinical trials

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that a European trial application has been filed by Novo Nordisk A/S for IPH2201 (NN8765). This triggered the payment to Innate Pharma of a significant undisclosed milestone. IPH2201 is a humanized antibody generated in the collaboration between Innate Pharma and Novo Nordisk A/S and developed to treat patients with chronic inflammatory and auto-immune diseases.